Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:54 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation
NCT03839355 · Mayo Clinic · PHASE3 · terminated · last registry update 2021-03-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study terminated due to slower than anticipated enrollment.” | – | Registry record, Mayo Clinic |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against F10 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-02-07Phase 3 first posted: Medical University of Vienna, Argatroban + Unfractionated heparin (NCT05226442)
- 2022-01-24Phase 3 first posted: Shanghai Xinzhi BioMed Co., Ltd., Single dose intravenous injection of BBM-H901 (NCT05203679)
- 2022-01-20Phase 3 first posted: University Hospital, Brest, Direct Oral Anticoagulants + Low-dose aspirin (NCT05198960)
- 2021-12-28Phase 3 first posted: Anthos Therapeutics, Inc., Abelacimab + Apixaban (NCT05171049)
- 2021-12-14Phase 3 first posted: Takeda, TAK-330 + SOC 4F-PCC (NCT05156983)
- 2021-12-06Phase 3 first posted: Pfizer, PF-06741086 (NCT05145127)
- 2021-11-16Phase 3 first posted: University of Sao Paulo, ASA + Clopidogrel (NCT05122455)
- 2021-10-14Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Rivaroxaban 2.5 MG [Xarelto] + DAPT strategy (NCT05077683)
- 2021-09-17Phase 3 first posted: University of Florida, Ticagrelor + Aspirin + Rivaroxaban + Aspirin (NCT05047172)
- 2021-09-05Phase 3 first posted: Oslo University Hospital, Acetylsalicylic acid + Apixaban (NCT05035277)
- 2021-09-02Phase 3 first posted: University Health Network, Toronto, Rivaroxaban 10 MG + Placebo (NCT05033314)
- 2021-08-31Phase 3 first posted: Ottawa Hospital Research Institute, Rivaroxaban 10 MG (NCT05029063)
- 2021-07-22Results posted on the registry: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, rivaroxaban + Warfarin (NCT02376010)
- 2021-04-30Phase 3 first posted: Octapharma, Octaplex (NCT04867837)
- 2021-01-29Phase 3 first posted: Kyushu University, Edoxaban + Warfarin Potassium (NCT04730037)
- 2020-12-02Phase 3 first posted: Thomas L. Ortel, Apixaban 2.5 MG + Placebo (NCT04650087)
- 2020-09-24Phase 3 first posted: Emory University, Emicizumab + FEIBA (NCT04563520)
- 2020-06-16Phase 3 first posted: Hoffmann-La Roche, Emicizumab (NCT04431726)
- 2020-03-27Phase 3 first posted: Population Health Research Institute, Colchicine + Interferon-Beta (NCT04324463)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision